β-シクロデキストリン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H332：吸入すると有害

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P304+P340：吸入した場合：空気の新鮮な場所に移し、呼吸しやすい 姿勢で休息させること。

β-シクロデキストリン 価格

β-シクロデキストリン 化学特性,用途語,生産方法

• 外観

  白色～ほとんど白色, 結晶性粉末～粉末

• 定義

  本品は、6~8のグルコピラノースからなる環状多糖類であり、次の化学式で表される。
  環状構造：6~8

• 溶解性

  水に易溶, エタノール及びアセトンにほとんど不溶。水に溶けやすく、エタノール及びアセトンにほとんど溶けない。

• 用途

  光学分割剤。

• 化粧品の成分用途

  キレート剤、吸着剤

• 効能

  封鎖剤

• 化学的特性

  white powder

• 天然物の起源

  A derivative of naturally occurring starch.

• 使用

  β-Cyclodextrin is a cyclic oligosaccharide produced from starch via enzymatic conversion. β-Cyclodextrin is commonly used to produce HPLC columns allowing chiral enantiomers separation.

• 調製方法

  Cyclodextrins are manufactured by the enzymatic degradation of starch using specialized bacteria. For example, β-cyclodextrin is produced by the action of the enzyme cyclodextrin glucosyltransferase upon starch or a starch hydrolysate. An organic solvent is used to direct the reaction that produces β-cyclodextrin, and to prevent the growth of microorganisms during the enzymatic reaction. The insoluble complex of β-cyclodextrin and organic solvent is separated from the noncyclic starch, and the organic solvent is removed in vacuo so that less than 1 ppm of solvent remains in the β-cyclodextrin. The β-cyclodextrin is then carbon treated and crystallized from water, dried, and collected.

• 製造方法

  Usually produced commercially from Bacillus macerans or B. circulans fermentation of starch or starch hydrolysate.

• 精油の成分

  In addition to carvone, the oil contains d-limonene, carveol, diacetyl furfural, methyl alcohol, acetic aldehyde and other substances. Caraway oil consists of 3.5 to 7% volatile and fatty oils; resin, sugar, tannin, mucilage.

• 一般的な説明

  Beta-Cyclodextrin is the most abundant and cheap cyclic oligosaccharide that forms inclusion complexes with several drug molecules. Its main application is in tablet and capsule formulations.
  Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

• 安全性

  Cyclodextrins are starch derivatives and are mainly used in oral and parenteral pharmaceutical formulations. They are also used in topical and ophthalmic formulations.
  Cyclodextrins are also used in cosmetics and food products, and are generally regarded as essentially nontoxic and nonirritant materials. However, when administered parenterally, β-cyclodextrin is not metabolized but accumulates in the kidneys as insoluble cholesterol complexes, resulting in severe nephrotoxicity.
  Cyclodextrin administered orally is metabolized by microflora in the colon, forming the metabolites maltodextrin, maltose, and glucose; these are themselves further metabolized before being finally excreted as carbon dioxide and water. Although a study published in 1957 suggested that orally administered cyclodextrins were highly toxic, more recent animal toxicity studies in rats and dogs have shown this not to be the case, and cyclodextrins are now approved for use in food products and orally administered pharmaceuticals in a number of countries.
  Cyclodextrins are not irritant to the skin and eyes, or upon inhalation. There is also no evidence to suggest that cyclodextrins are mutagenic or teratogenic.
  β-Cyclodextrin
  LD50 (mouse, IP): 0.33 g/kg(16)
  LD50 (mouse, SC): 0.41 g/kg
  LD50 (rat, IP): 0.36 g/kg
  LD50 (rat, IV): 1.0 g/kg
  LD50 (rat, oral): 18.8 g/kg
  LD50 (rat, SC): 3.7 g/kg

• 貯蔵

  Cyclodextrins should be stored in a tightly sealed container, in a cool, dry place.Cyclodextrins are stable in the solid state if protected from high humidity.

• 純化方法

  Recrystallise β-cyclodextrin from water and dry it for 12hours in a vacuum at 110o, or 24hours in a vacuum at 70o. The purity is assessed by TLC on cellulose containing a fluorescent indicator. [Taguchi, J Am Chem Soc 108 2705 1986, Tabushi et al. J Am Chem Soc 108 4514 1986, Orstam & Ross J Phys Chem 91 2739 1987.] [Beilstein 19 IV 6287, 19/12 V 801.]

• 規制状況(Regulatory Status)

  Included in the FDA Inactive Ingredients Database: α-cyclodextrin (injection preparations); β-cyclodextrin (oral tablets, topical gels); γ-cyclodextrin (IV injections).
  Included in the Canadian List of Acceptable Non-medicinal Ingredients (stabilizing agent; solubilizing agent ); and in oral and rectal pharmaceutical formulations licensed in Europe, Japan, and the USA.

β-シクロデキストリン 上流と下流の製品情報

β-シクロデキストリン 生産企業

Global(637)Suppliers

β-シクロデキストリン スペクトルデータ(IR1、IR2、MS)

7585-39-9, β-シクロデキストリン キーワード